Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1–45 years: a Danish cohort study
Rattachement africain : dk. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
With increasing survival in acute lymphoblastic leukemia (ALL), long-term toxicities have become a critical aspect. A novel measure, designated Severe Toxicity-free survival (STFS), was developed through international consensus to integrate the most severe, symptomatic organ toxicities in outcome evaluation. This measure has not been applied to real-world data before. We assessed the incidence of 21 predefined Severe Toxicities in a nationwide cohort of 506 ALL patients aged 1-45 years treated according to the NOPHO ALL2008 protocol. At five years, event-free survival was 84.4% (95% CI: 81.3-87.7%) and Severe Toxicity-event-free survival was 78.4% (95% CI: 74.9-82.1%), with significantly lower values in adults (aged 18-45 years) than children (61.6% [52.6-72.2%] vs 82.4% [78.8-86.2%]; log-rank p < 0.001). The most common Severe Toxicities were severe osteonecrosis limiting activities of daily function (N = 20) and disabling paralytic and neuropathic conditions (N = 16). Exploratory analyses showed that 10-17-year-olds had the highest risk of Severe Toxicities similar to that of adults. These findings highlight a burden of severe, long-term toxicities in ALL survivors overlooked by traditional outcome measures, also following frontline therapy only. STFS should be incorporated in future trials for meaningful outcome evaluation and international comparisons across treatment strategies.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1–45 years: a Danish cohort study
- Date Crossref
- 10/02/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Copenhagen University Hospital Department of Pediatrics and Adolescent Medicine pays non établi dans la noticeÉtablissement de santé
-
Danish Cancer Society pays non établi dans la noticeOrganisation à but non lucratif
-
Aarhus University Hospital Department of Child and Adolescent Medicine pays non établi dans la noticeÉtablissement de santé
-
Odense University Hospital Department of Hematology pays non établi dans la noticeOrganisme public
-
Rigshospitalet pays non établi dans la noticeÉtablissement de santé
-
Aalborg University Hospital Pediatric Department pays non établi dans la noticeÉtablissement de santé
-
University of Southern Denmark Department of Clinical Research pays non établi dans la noticeUniversité ou école supérieure
-
Danish Cancer Institute Hematology pays non établi dans la noticeStructure de recherche
-
Network for Adolescents and Young Adults Cancer Research in Denmark (NAYAcare DK) pays non établi dans la noticeInstitution
Department of Pediatrics and Adolescent Medicine — Copenhagen University Hospital, Danish Cancer Society et Department of Child and Adolescent Medicine — Aarhus University Hospital, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.